Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | acetylcholinesterase | 0.2056 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.2056 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.2056 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.2056 | 0.5 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.2056 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.2056 | 0.5 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.2056 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2056 | 0.5 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.2056 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.2056 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.2056 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2056 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
logP (ADMET) | = -0.36 | Partition coefficient (logP) | ChEMBL. | 3091833 |
MED (functional) | = 25.6 mg kg-1 | Antitumor activity against P-388 leukemia in mice , activity is expressed as Minimum effective dose | ChEMBL. | 3091833 |
OD (functional) | = 25.6 mg kg-1 | Antitumor activity against P-388 leukemia in mice , activity is expressed as Optimal dose | ChEMBL. | 3091833 |
Ratio (functional) | = 1 | Ratio value, Optimal dose / Minimum effective dose | ChEMBL. | 3091833 |
T/C (functional) | = 137 % | Antitumor activity against P-388 leukemia in mice , activity is expressed as maximum effect (% T/C) = MST(median survival time) treated/ MST control in the presence of compound only | ChEMBL. | 3091833 |
T/C (functional) | = 279 % | Antitumor activity against P-388 leukemia in mice , activity is expressed as maximum effect (% T/C) = MST(median survival time) treated/ MST control in the present of Mitomycin C | ChEMBL. | 3091833 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.